

Clotinab[®] (abciximab)

For intravenous administration

DESCRIPTION:

Abciximab, Clotinab[®], is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin receptor found on platelets and vessel wall endothelial and smooth muscle cells.

The chimeric 7E3 antibody is produced by mammalian cell culture. The 47,615 dalton Fab fragment is purified from cell culture supernatant by a series of steps involving specific viral inactivation and removal procedures, digestion with papain and column chromatography.

Clotinab[®] is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use. Each single use vial contains 2 mg/mL of Abciximab in a buffered solution (pH 7.2) of 0.01 M sodium phosphate, 0.15 M sodium chloride and 0.001% polysorbate 80 in Water for Injection. No preservatives are added.

CLINICAL PHARMACOLOGY:

General

Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. The mechanism of action is thought to involve steric hindrance and/or conformational effects to block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa.

Abciximab binds with similar affinity to the vitronectin receptor, also known as the $\alpha v\beta_3$ integrin. The vitronectin receptor mediates the procoagulant properties of platelets and the proliferative properties of vascular endothelial and smooth muscle cells. In *in vitro* studies using a model cell line derived from melanoma cells, Abciximab blocked $\alpha v\beta_3$ mediated effects including cell adhesion ($IC_{50} = 0.34\mu\text{g/mL}$). At concentrations which, *in vitro*, provide >80% GPIIb/IIIa receptor blockade, but above the *in vivo* therapeutic range, Abciximab more effectively blocked the burst of thrombin generation that followed platelet activation than select comparator antibodies which inhibit GPIIb/IIIa alone. The

relationship of these *in vitro* data to clinical efficacy is unknown.

Pre-clinical experience

Maximal inhibition of platelet aggregation was observed when $\geq 80\%$ of GPIIb/IIIa receptors were blocked by Abciximab. In non-human primates, Abciximab bolus doses of 0.25 mg/kg generally achieved a blockade of at least 80% of platelet receptors and fully inhibited platelet aggregation. Inhibition of platelet function was temporary following a bolus dose, but receptor blockade could be sustained at $\geq 80\%$ by continuous intravenous infusion. The inhibitory effects of Abciximab were substantially reversed by the transfusion of platelets in monkeys. The antithrombotic efficacy of prototype antibodies (murine 7E3 Fab and F(ab')₂) and Abciximab was evaluated in dog, monkey and baboon models of coronary, carotid, and femoral artery thrombosis. Doses of the murine version of 7E3 or Abciximab sufficient to produce high-grade ($\geq 80\%$) GPIIb/IIIa receptor blockade prevented acute thrombosis and yielded lower rates of thrombosis compared with aspirin and/or heparin.

Pharmacokinetics

Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors. Platelet function generally recovers over the course of 48 hours, although Abciximab remains in the circulation for 15 days or more in a platelet-bound state. Intravenous administration of a 0.25 mg/kg bolus dose of Abciximab followed by continuous infusion of 10 $\mu\text{g}/\text{min}$ (or a weight-adjusted infusion of 0.125 $\mu\text{g}/\text{kg}/\text{min}$ to a maximum of 10 $\mu\text{g}/\text{min}$) produces approximately constant free plasma concentrations throughout the infusion. At the termination of the infusion period, free plasma concentrations fall rapidly for approximately six hours then decline at a slower rate.

Pharmacodynamics

Intravenous administration in humans of single bolus doses of Abciximab from 0.15 mg/kg to 0.30 mg/kg produced rapid dose-dependent inhibition of platelet function as measured by *ex vivo* platelet aggregation in response to adenosine diphosphate (ADP) or by prolongation of bleeding time. At the two highest doses (0.25 and 0.30 mg/kg) at two hour post injection, over 80% of the GPIIb/IIIa receptors were blocked and platelet aggregation in response to 20 μM ADP was almost abolished. The median bleeding time increased to over 30 minutes at both doses compared with a baseline value of approximately five minutes.

Intravenous administration in humans of a single bolus dose of 0.25 mg/kg followed by a continuous infusion of 10 $\mu\text{g}/\text{min}$ for periods of 12 to 96 hours produced sustained high-grade GPIIb/IIIa receptor blockade ($\geq 80\%$) and inhibition of platelet function (*ex vivo* platelet aggregation in response to 5 μM or 20 μM ADP less than 20% of baseline and bleeding time greater than 30 minutes) for the duration of the infusion in most patients. Similar results were obtained when a weight-adjusted infusion dose (0.125 $\mu\text{g}/\text{kg}/\text{min}$ to a maximum of 10 $\mu\text{g}/\text{min}$) was used in patients weighing up to 80kg. Results in patients who received the 0.25 mg/kg bolus followed by a 5 $\mu\text{g}/\text{min}$ infusion for 24 hours showed a similar initial receptor blockade and inhibition of platelet aggregation, but the response

was not maintained throughout the infusion period.

Low levels of GPIIb/IIIa receptor blockade are present for more than 10 days following cessation of the infusion. After discontinuation of Abciximab infusion, platelet function returns gradually to normal. Bleeding time returned to ≤ 12 minutes within 12 hours following the end of infusion in 15 of 20 patients (75%), and within 24 hours in 18 of 20 patients (90%). *Ex vivo* platelet aggregation in response to 5 μ M ADP returned to $\geq 50\%$ of baseline within 24 hours following the end of infusion in 11 of 32 patients (34%) and within 48 hours in 23 of 32 patients (72%). In response to 20 μ M ADP, *ex vivo* platelet aggregation returned to $\geq 50\%$ of baseline within 24 hours in 20 of 32 patients (62%) and within 48 hours in 28 of 32 patients (88%).

Anticoagulation:

Due to the incidence of bleeding seen in the EPIC trial, the dosing regimens of concomitant heparin and the target levels for anticoagulation were successively varied in the CAPTURE and EPILOG trials. These modified dosing regimens combined with other measures for patient management were associated with reduced bleeding rates (see ADVERSE REACTIONS: Bleeding).

EPILOG trial: Heparin was weight adjusted in all treatment arms. A baseline ACT was determined prior to percutaneous coronary intervention. In the low-dose heparin arm of the trial, heparin was administered as follows:

The initial heparin bolus was based upon the results of the baseline ACT, according to the following regimen:

ACT < 150 seconds: administer 70 U/kg heparin

ACT 150 ~ 199 seconds: administer 50 U/kg heparin

ACT \geq 200 seconds: administer no heparin

Additional 20 U/kg heparin boluses were given to achieve and maintain an ACT of 200 seconds during the procedure.

Discontinuation of heparin immediately after the procedure and removal of the arterial sheath within six hours were strongly recommended in the trial. If prolonged heparin therapy or delayed sheath removal was clinically indicated, heparin was adjusted to keep the APTT at a target of 60 to 85 seconds.

CAPTURE trial: Anticoagulation was initiated prior to the administration of Abciximab. Anticoagulation was initiated with an intravenous heparin infusion to achieve a target APTT of 60 to 85 seconds. The heparin infusion was not uniformly weight adjusted in this trial. The heparin infusion was maintained during the Abciximab infusion and was adjusted to achieve an ACT of 300 seconds or an APTT of 70 seconds during the percutaneous coronary intervention. Following the intervention, heparin management was as outlined above for the EPILOG trial.

INDICATIONS AND USAGE:

Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications:

- in patients undergoing percutaneous coronary intervention
- in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours.

Safety and efficacy of Abciximab use in patients not undergoing percutaneous coronary intervention have not been established.

Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.

CONTRAINDICATIONS:

Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:

- Active internal bleeding
- Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance
- History of cerebrovascular accident (CVA) within two years, or CVA with a significant residual neurological deficit
- Bleeding diathesis
- Administration of oral anticoagulants within seven days unless prothrombin time is \leq 1.2 times control
- Thrombocytopenia ($< 100,000$ cells/ μL)
- Recent (within six weeks) major surgery or trauma
- Intracranial neoplasm, arteriovenous malformation, or aneurysm
- Severe uncontrolled hypertension
- Presumed or documented history of vasculitis
- Use of intravenous dextran before percutaneous coronary intervention, or intent to use it during an intervention

Abciximab is also contraindicated in patients with known hypersensitivity to any component of this product or to murine proteins.

WARNINGS:

Abciximab has the potential to increase the risk of bleeding, particularly in the presence of anticoagulation, e.g., from heparin, other anticoagulants, or thrombolytics (see ADVERSE REACTIONS: Bleeding).

The risk of major bleeds due to Abciximab therapy is increased in patients receiving thrombolytics and should be weighed against the anticipated benefits.

Should serious bleeding occur that is not controllable with pressure, the infusion of Abciximab and concomitant heparin should be stopped.

PRECAUTIONS:

Bleeding Precautions

Results of the EPILOG trial show that bleeding can be reduced by the use of low-dose, weight-adjusted heparin regimens, adherence to stricter anticoagulation guidelines, early femoral arterial sheath removal, careful patient and access site management and weight-adjustment of the Abciximab infusion dose. Therapy with Abciximab requires careful attention to all potential bleeding sites including catheter insertion sites, arterial and venous puncture sites, cutdown sites, needle puncture sites, and gastrointestinal, genitourinary, and retroperitoneal sites.

Arterial and venous punctures, intramuscular injections, and use of urinary catheters, nasotracheal intubation, nasogastric tubes and automatic blood pressure cuffs should be minimized. When obtaining intravenous access, non-compressible sites (e.g., subclavian or jugular veins) should be avoided. Saline or heparin locks should be considered for blood drawing. Vascular puncture sites should be documented and monitored. Gentle care should be provided when removing dressings.

Femoral artery access site

Arterial access site care is important to prevent bleeding. Care should be taken when attempting vascular access that only the anterior wall of the femoral artery is punctured, avoiding a Seldinger (through and through) technique for obtaining sheath access. Femoral vein sheath placement should be avoided unless needed. While the vascular sheath is in place, patients should be maintained on complete bed rest with the head of the bed $\leq 30^\circ$ and the affected limb restrained in a straight position. Patients may be medicated for back/groin pain as necessary.

Discontinuation of heparin immediately upon completion of the procedure and removal of the arterial sheath within six hours is strongly recommended if APTT ≤ 50 sec or ACT ≤ 175 sec (See PRECAUTIONS: Laboratory Tests). In all circumstances, heparin should be discontinued at least two hours prior to arterial sheath removal. Following sheath removal, pressure should be applied to the femoral artery for at least 30 minutes using either manual compression or a mechanical device for hemostasis. A pressure dressing should be applied following hemostasis. The patient should be maintained on bed rest for six to eight hours following sheath removal or discontinuation of Abciximab, or four hours following discontinuation of heparin, whichever is later. The pressure dressing should be removed prior to ambulation. The sheath insertion site and distal pulses of affected leg(s) should be frequently checked while the femoral artery sheath is in place and for six hours after femoral artery sheath removal. Any hematoma should be measured and monitored for enlargement.

The following conditions have been associated with an increased risk of bleeding and may be additive with the effect of Abciximab in the angioplasty setting: percutaneous coronary intervention within 12 hours of the onset of symptoms for acute myocardial infarction, prolonged percutaneous coronary intervention (lasting more than 70 minutes) and failed percutaneous coronary intervention.

Use of Thrombolytics, Anticoagulants and Other Antiplatelet Agents

In the EPIC, EPILOG and CAPTURE trials, Abciximab was used concomitantly with heparin and aspirin. Because Abciximab inhibits platelet aggregation, caution should be employed when it is used with other drugs that affect hemostasis, including thrombolytics, oral anticoagulants, non-steroidal anti-inflammatory drugs, dipyridamole, and ticlopidine.

In the EPIC trial, there was limited experience with the administration of Abciximab with low molecular weight dextran. Low molecular weight dextran was usually given for the deployment of a coronary stent, for which oral anticoagulants were also given. In the 11 patients who received low molecular weight dextran with Abciximab, five had major bleeding events and four had minor bleeding events. None of the five placebo patients treated with low molecular weight dextran had a major or minor bleeding event (see CONTRAINDICATIONS). There are limited data on the use of Abciximab in patients receiving thrombolytic agents. Because of concern about synergistic effects on bleeding, systemic thrombolytic therapy should be used judiciously.

Thrombocytopenia

Platelet counts should be monitored prior to treatment, two to four hours following the bolus dose of Abciximab and at 24 hours or prior to discharge, whichever is first. If a patient experiences an acute platelet decrease (e.g., a platelet decrease to less than 100,000 cells/ μ L and a decrease of at least 25% from pre-treatment value), additional platelet counts should be determined. These platelet counts should be drawn in three separate tubes containing ethylenediaminetetraacetic acid (EDTA), citrate and heparin, respectively, to exclude pseudothrombocytopenia due to *in vitro* anticoagulant interaction. If true thrombocytopenia is verified, Abciximab should be immediately discontinued and the condition appropriately monitored and treated. For patients with thrombocytopenia in the clinical trials, a daily platelet count was obtained until it returned to normal. If a patient's platelet count dropped to 60,000 cells/ μ L, heparin and aspirin were discontinued. If a patient's platelet count dropped below 50,000 cells/ μ L, platelets were transfused. Most cases of severe thrombocytopenia (~50,000 cells/ μ L) occurred within the first 24 hours of Abciximab administration.

Restoration of Platelet Function

In the event of serious uncontrolled bleeding or the need for emergency surgery, Abciximab should be discontinued. If platelet function does not return to normal, it may be restored, at least in part, with platelet transfusions.

Laboratory Tests

Before infusion of Abciximab, platelet count, prothrombin time, ACT and APTT should be measured to identify pre-existing hemostatic abnormalities

Based on an integrated analysis of data from all studies, the following guidelines may be utilized to minimize the risk for bleeding.

When Abciximab is initiated 18 to 24 hours before percutaneous coronary intervention, the APTT should be maintained between 60 and 85 seconds during the Abciximab and heparin infusion period. During percutaneous coronary intervention the ACT should be maintained between 200 and 300 seconds. If anticoagulation is continued in these patients following percutaneous coronary intervention, the APTT should be maintained between 55 and 75 seconds. The APTT or ACT should be checked prior to arterial sheath

removal. The sheath should not be removed unless APTT \leq 50 seconds or ACT \leq 175 seconds.

Readministration

Administration of Abciximab may result in human anti-chimeric antibody (HACA) formation that could potentially cause allergic or hypersensitivity reactions including anaphylaxis), thrombocytopenia or diminished benefit upon readministration of Abciximab. In the EPIC, EPILOG, and CAPTURE trials, positive HACA responses occurred in approximately 5.8% of the Abciximab-treated patients. There was no excess of hypersensitivity or allergic reactions related to Abciximab treatment.

Readministration of Abciximab to 29 healthy volunteers who had not developed a HACA response after first administration has not led to any change in Abciximab pharmacokinetics or to any reduction in antiplatelet potency. However, results in this small group of patients suggest that the incidence of HACA response may be increased after readministration. Readministration to patients who have developed a positive HACA response after initial administration has not been evaluated in clinical trials.

Allergic Reactions

Anaphylaxis has not been reported for Abciximab-treated patients in any of the Phase 3 clinical trials. However, anaphylaxis may occur. If it does, administration of Abciximab should be immediately stopped and standard appropriate resuscitative measures should be initiated.

Drug Interactions

Although drug interactions with Abciximab have not been studied systematically, Abciximab has been administered to patients with ischemic heart disease treated concomitantly with a broad range of medications used in the treatment of angina, myocardial infarction and hypertension. These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine and aspirin. Heparin, other anticoagulants, thrombolytics, and antiplatelet agents may be associated with an increase in bleeding. Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.

Carcinogenesis, Mutagenesis and Impairment of Fertility

In vitro and *in vivo* mutagenicity studies have not demonstrated any mutagenic effect. Long-term studies in animals have not been performed to evaluate the carcinogenic potential or effects on fertility in male or female animals.

Pregnancy Category C

Animal reproduction studies have not been conducted with Abciximab. It is also not known whether Abciximab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Abciximab should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk, caution should be exercised when Abciximab is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been studied.

ADVERSE REACTIONS:

Bleeding

Abciximab has the potential to increase the risk of bleeding, particularly in the presence of anticoagulation, e.g., from heparin, other anticoagulants or thrombolytics. Bleeding in the Phase 3 trials was classified as major, minor or insignificant by the criteria of the Thrombolysis in Myocardial Infarction study group. Major bleeding events were defined as either an intracranial hemorrhage or a decrease in hemoglobin greater than 5 g/dL. Minor bleeding events included spontaneous gross hematuria, spontaneous hematemesis, observed blood loss with a hemoglobin decrease of more than 3 g/dL, or a decrease in hemoglobin of at least 4 g/dL without an identified bleeding site. Insignificant bleeding events were defined as a decrease in hemoglobin of less than 3 g/dL or a decrease in hemoglobin between 3~4 g/dL without observed bleeding. In patients who received transfusions, the number of units of blood lost was estimated through an adaptation of the method of Landefeld, et al.

In the EPIC trial, in which a non-weight-adjusted, standard heparin dose regimen was used, the most common complication during Abciximab therapy was bleeding during the first 36 hours. The incidences of major bleeding, minor bleeding and transfusion of blood products were significantly increased. Approximately 70% of Abciximab-treated patients with major bleeding had bleeding at the arterial access site in the groin. Abciximab treated patients also had a higher incidence of major bleeding events from gastrointestinal, genitourinary, retroperitoneal, and other sites.

Bleeding rates were reduced in the CAPTURE trial, and further reduced in the EPILOG trial by use of modified dosing regimens and specific patient management techniques. In EPILOG, using the heparin and Abciximab dosing, sheath removal and arterial access site guidelines described under PRECAUTIONS, the incidence of major bleeding in patients treated with Abciximab and low-dose, weight-adjusted heparin was not significantly different from that in patients receiving placebo.

Subgroup analyses in the EPIC and CAPTURE trials showed that non-CABG major bleeding was more common in Abciximab patients weighing ≤ 75 kg. In the EPILOG trial, which used weight-adjusted heparin dosing, the non-CABG major bleeding rates for Abciximab-treated patients did not differ substantially by weight subgroup.

Although data are limited, Abciximab treatment was not associated with excess major bleeding in patients who underwent CABG surgery. (The range among all treatment arms was 3~5% in EPIC and 1~2% in the CAPTURE and EPILOG trials.) Some patients with prolonged bleeding times received platelet transfusions to correct the bleeding time prior

to surgery (See PRECAUTIONS: Restoration of platelet Function).

The rates of major bleeding, minor bleeding and bleeding events requiring transfusions in the CAPTURE, EPILOG, and EPISTENT trials are shown in Table 1. The rates of insignificant bleeding events are not included in Table 1.

Table 1. NON-CABG BLEEDING IN THE EPISTENT, EPILOG AND CAPTURE TRIALS

	Number of Patients with Bleeds (%)		
EPILOG and EPISTENT:		Abciximab + Low-dose Heparin ^d	Abciximab + Standard dose Heparin ^e (n=918)
	Placebo ^c (n=1748)	(n=2525)	
Major ^a	18 (1.0)	21 (0.8)	17 (1.9)
Minor	46 (2.6)	82 (3.2)	70 (7.6)
Requiring transfusion ^b	15 (0.9)	13 (0.5)	7(0.8)
CAPTURE:			Abciximab ^f
	Placebo ^f (n=635)		(n=630)
Major ^a	12 (1.9)		24 (3.8)
Minor	12 (2.0)		30 4.8)
Requiring transfusion ^b	9(1.4)		15 (2.4)

^aPatients who had bleeding in more than one classification are counted only once according to the most severe classification.

Patients with multiple bleeding events of the same classification are also counted once within that classification.

^bPatients with major non-CABG bleeding who received packed red blood cells or whole blood transfusion

^cStandard-dose heparin with or without stent (EPILOG and EPISTENT)

^dLow-dose heparin with or without stent (EPILOG and EPISTENT)

^eStandard-dose heparin (EPILOG)

^fStandard-dose heparin (CAPTURE)

Intracranial Hemorrhage and Stroke

The total incidence of intracranial hemorrhage and non-hemorrhagic stroke across all three trials was not significantly different, 7/2225 for placebo patients and 10/3112 for Abciximab treated patients. The incidence of intracranial hemorrhage was 3/2225 for placebo patients and 6/3112 for Abciximab patients.

Thrombocytopenia

In the clinical trials, patients treated with Abciximab were more likely than patients treated with placebo to experience decreases in platelet counts. The rates of thrombocytopenia and transfusions were lower in the subsequent CAPTURE and EPILOG trials (Table 2).

Table 2. THROMBOCYTOPENIA AND PLATELET TRANSFUSIONS^a

	Placebo + Standard dose Heparin	Abciximab + Standard dose Heparin	Abciximab + Low dose Heparin
	Total number of patients enrolled		
EPIC	N = 696	N = 708	-
CAPTURE	N = 635	N = 630	-
EPILOG	N = 939	N = 918	N=935
Patients with disease of platelet to <50,000cells/ μ L ^a		% of patients with events	
EPIC	0 .7	1.6	-
CAPTURE	0.3	1.7	-
EPILOG	0.4	0.9	0.4
Patients with disease of platelet to <100,000cells/ μ L ^a			
EPIC	3 .4	5.2	-
CAPTURE	1.3	5.6	-
EPILOG	1.5	2.6	2.5
Patients with received platelet transfusions			
EPIC	2 .6	5.5	-
CAPTURE	0.3	2.1	-
EPILOG	1.1	1.6	0.9

^aPatients with a platelet count of <50,000 cells/ μ L are also included in the category of patients with a platelet count of <100,000 cells/ μ L.

^bIncludes patients receiving platelet transfusions for thrombocytopenia or any other reason.

Other Adverse Reactions

Table 3 shows adverse events other than bleeding and thrombocytopenia from the combined EPIC, EPILOG and CAPTURE trials which occurred in patients in the bolus plus infusion arm at an incidence of more than 0.5% higher than in those treated with placebo.

Table 3. ADVERSE EVENTS AMONG TREATED PATIENTS IN THE EPIC, EPILOG AND CAPTURE TRIALS

Events	Placebo (n = 2226)	Bolus + Infusion (n = 3111)
	Number of Patients (%)	

Cardiovascular System		
Hypertension	230 (10.3)	447 (14.4)
Bradycardia	79 (3.5)	140 (4.5)
Gastrointestinal System		
Nausea	255 (11.5)	423 (13.6)
Vomiting	152 (6.8)	226 (7.3)
Abdominal Pain	49 (2.2)	97 (3.1)
Miscellaneous		
Back Pain	304 (13.7)	546 (17.6)
Chest Pain	208 (9.3)	356 (11.4)
Headache	122 (5.5)	200 (6.4)
Puncture Site Pain	58 (2.6)	113 (3.6)
Peripheral Edema	25 (1.1)	49 (1.6)

The following additional adverse events from the EPIC, EPILOG and CAPTURE trials were reported by investigators for patients treated with a bolus plus infusion of Abciximab at incidences which were less than 0.5% higher than for patients in the placebo arm.

- Cardiovascular System - ventricular tachycardia (1.4%), pseudoaneurysm (0.8%), palpitation (0.5%), arteriovenous fistula (0.4%), incomplete AV block (0.3%), nodal arrhythmia (0.2%), complete AV block (0.1%), embolism (limb)(0.1%); thrombophlebitis (0.1%);
- Gastrointestinal System - dyspepsia (2.1%), diarrhea (1.1%), ileus (0.1%), gastro-esophageal reflux (0.1%);
- Hemic and Lymphatic System - anemia (1.3%), leukocytosis (0.5%), petechiae (0.2%);
- Nervous System - dizziness (2.9%), anxiety (1.7%), abnormal thinking (1.3%), agitation (0.7%), hypesthesia (0.6%), confusion (0.5%), muscle contractions (0.4%), coma (0.2%), hypertonia (0.2%), diplopia (0.1%);
- Respiratory System - pneumonia (0.4%), rales (0.4%), pleural effusion (0.3%), bronchitis (0.3%), bronchospasm (0.3%), pleurisy (0.2%), pulmonary embolism (0.2%), rhonchi (0.1%);
- Musculoskeletal System - myalgia (0.2%);
- Urogenital System - urinary retention (0.7%), dysuria (0.4%), abnormal renal function (0.4%), frequent micturition (0.1%), cystalgia (0.1%), urinary incontinence (0.1%), prostatitis (0.1%);
- Miscellaneous - pain (5.4%), sweating increased (1.0%), asthenia (0.7%), incisional pain (0.6%), pruritus (0.1%), abnormal vision (0.3%), edema (0.3%), wound (0.2%), abscess (0.2%), cellulitis (0.2%), peripheral coldness (0.2%), injection site pain (0.1%), dry mouth (0.1%), pallor(0.1%), diabetes mellitus (0.1%), hyperkalemia (0.1%), enlarged abdomen (0.1 %), bullous eruption (0.1%), inflammation (0.1 %), drug toxicity (0.1%).

OVERDOSAGE:

There has been no experience of overdosage in human clinical trials.

DOSAGE AND ADMINISTRATION:

The safety and efficacy of Abciximab have only been investigated with concomitant administration of heparin and aspirin.

In patients with failed percutaneous coronary interventions, the continuous infusion of Abciximab should be stopped because there is no evidence for Abciximab efficacy in that setting.

In the event of serious bleeding that cannot be controlled by compression, Abciximab and heparin should be discontinued immediately.

The recommended dosage of Abciximab in adults is a 0.25 mg/kg intravenous bolus administered 10 ~ 60 minutes before the start of percutaneous coronary intervention, followed by a continuous intravenous infusion of 0.125 µg/kg/min (to a maximum of 10 µg/min) for 12 hours.

Patients with unstable angina not responding to conventional medical therapy and who are planned to undergo percutaneous coronary intervention within 24 hours may be treated with an Abciximab 0.25 mg/kg intravenous bolus followed by an 18 to 24-hour intravenous infusion of 10 µg/min, concluding one hour after the percutaneous coronary intervention.

Instructions for Administration

1. Parenteral drug products should be inspected visually for particulate matter prior to administration. Preparations of Abciximab containing visibly opaque particles should NOT be used.
2. Hypersensitivity reactions should be anticipated whenever protein solutions such as Abciximab are administered. Epinephrine, dopamine, theophylline, antihistamines and corticosteroids should be available for immediate use. If symptoms of an allergic reaction or anaphylaxis appear, the infusion should be stopped and appropriate treatment given.
3. As with all parenteral drug products, aseptic procedures should be used during the administration of Abciximab.
4. Withdraw the necessary amount of Abciximab for bolus injection into a syringe. Filter the bolus injection using a sterile, non-pyrogenic, low protein-binding 0.2 or 0.22 µm filter (Millipore SLGV025LS or equivalent).
5. Withdraw the necessary amount of Abciximab for the continuous infusion into a syringe. Inject into an appropriate container of sterile 0.9% saline or 5% dextrose and infuse at the calculated rate via a continuous infusion pump. The continuous infusion should be filtered either upon admixture using a sterile, non-pyrogenic, low protein-binding 0.2 or 0.22 µm syringe filter (Millipore SLGV025LS or equivalent) or upon administration using an in-line, sterile, non-pyrogenic, low protein-binding 0.2 or 0.22 µm filter (Abbott #4524 or equivalent). Discard the unused portion at the end of the infusion.
6. No incompatibilities have been shown with intravenous infusion fluids or commonly

used cardiovascular drugs. Nevertheless, Abciximab should be administered in a separate intravenous line whenever possible and not mixed with other medications.

7. No incompatibilities have been observed with glass bottles or polyvinyl chloride bags and administration sets.

HOW SUPPLIED:

Clotinab®(Abciximab) 2 mg/mL is supplied in a 5 mL vial containing 10 mg.

Vials should be stored at 2 to 8°C (36 to 46°F). Do not freeze. Do not shake. Do not use beyond the expiration date. Discard any unused portion left in the vial.

Market Authorization Holder Manufacturer (Drug substance):

ISU Abxis Co., Ltd.

Daewoo Frontier Valley 1cha, 203-209ho, 219-221ho, 304ho, 16-25, Dongbaekjungang-ro, 16beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 17015, Republic of Korea
TEL. +82-31-696-4700

Manufacturer (Drug product):

KOREA VACCINE CO.,LTD.

128 Mongae-ro, Danwon-gu, Ansan-si, Gyeonggldo, Republic of Korea

09/27/21